Prevalence and mutational determinants of high tumor mutation burden in breast cancer
Romualdo Barroso‐Sousa, Esha Jain, Ofir Cohen, D. Kim, Jorge E. Buendia-Buendia, Eric P. Winer, NU Lin, Sara M. Tolaney, Nikhil Wagle
This study finds that 5% of breast cancers have high tumor mutation burden, more common in metastatic tumors, with APOBEC activity as the most common mutational process and potential benefit from PD-1 inhibitors.
Annals of Oncology · Jan 9, 2020Peer-reviewedGenomics